Takeda Joins BaseLaunch as Sixth Pharmaceutical Partner in Basel Biotech Incubator
核心洞察
Takeda (搜索) has joined BaseLaunch (搜索) as the sixth pharmaceutical partner, bringing the total number of leading pharma companies supporting the Basel-based biotech incubator to six partners.
BaseLaunch (搜索) has supported 27 biotech companies since 2018, with portfolio companies collectively raising over $1 billion and several advancing to Phase II clinical trials.
The partnership provides Takeda (搜索) access to European life sciences deal flow while offering expertise to help develop innovative therapeutics through BaseLaunch (搜索)'s company-building platform.
BaseLaunch (搜索), a Basel-based biotech incubator, announced that Takeda (搜索) has joined as its sixth pharmaceutical partner, expanding the platform's consortium of leading industry supporters. The strategic investment provides Takeda access to proven quality life sciences deal flow in central Europe and BaseLaunch's company-building capabilities, while contributing expertise in biotech innovation and medicine development.
Strategic Partnership Expands Industry Support
Through this partnership, Takeda (搜索) joins five existing pharmaceutical partners including AbbVie (搜索), Roche, Novo Nordisk, Johnson & Johnson, and CSL (搜索), along with venture fund Pureos Bioventures (搜索). The commitment from these prominent partners demonstrates the continued success of BaseLaunch (搜索)'s model, which deeply embeds portfolio companies in the Basel area, recognized as a hotspot of European biopharma innovation.
"We're thrilled to welcome Takeda (搜索) to BaseLaunch (搜索). This partnership will significantly benefit our early-stage biotech ventures," noted Stephan Emmerth, Director of BaseLaunch. "Early stage funding, coupled with our company-building capabilities and privileged access to our pharma partners, gives our ventures a head start to further build and grow their businesses."
Track Record of Success
Since its inception in 2018, BaseLaunch (搜索) has supported 27 biotech companies across various modalities and indications, with portfolio companies collectively raising over $1 billion. Several companies have advanced to Phase II clinical trials, demonstrating the incubator's ability to develop promising therapeutics through critical development stages.
The platform has achieved two notable exits, most prominently T3 Pharma (搜索), which was acquired by Boehringer Ingelheim for $500 million in 2023. This successful exit validates BaseLaunch (搜索)'s approach to identifying and developing high-value biotech ventures.
Enhanced Innovation Capabilities
"Our partnership with BaseLaunch (搜索) strengthens our connection to European biotech innovation," said Alison Handley, Head of the Center for External Innovation at Takeda (搜索). "Further, by joining the investment board, we can help guide company creation and apply Takeda's expertise in turning science into new therapies. We look forward to participating in BaseLaunch and advancing innovative medicines together."
The partnership will further enhance BaseLaunch (搜索)'s ability to develop its portfolio companies by combining early-stage funding with comprehensive company-building capabilities and privileged access to pharmaceutical partners' expertise. BaseLaunch operates as a platform to launch, fund, and build early biotech ventures developing cutting-edge therapeutics, providing financing and supporting all aspects of company creation and growth from inception through Series A funding.
The incubator is operationally run and financed by Basel Area Business & Innovation (搜索), the non-profit agency focused on promoting the Basel Area Life Sciences Supercluster as Europe's most concentrated destination for biotech, pharma, health tech, and MedTech innovation.